Using microRNAs to predict chemotherapy benefits in stage II colon cancer
microRNAs Tool for Stratifying Stage II Colon Cancer:a Perspective Study of Adjuvant Chemotherapy
This study is testing a new tool that looks at tiny molecules in the body to see if it can help doctors figure out which patients with stage II colon cancer might benefit from chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 630 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT02635087 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate a microRNA tool designed to predict which patients with stage II colon cancer may benefit from chemotherapy. Patients will provide postoperative specimens for analysis, and their treatment decisions will be made by their healthcare providers. The study will follow these patients to assess the tool's effectiveness in predicting prognosis based on their miRNA profiles.
Who should consider this trial
Good fit: Ideal candidates are patients with a confirmed diagnosis of stage II colon cancer who have not received prior anti-cancer treatment and have a good health rating.
Not a fit: Patients with severe comorbidities or contraindications to chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could help identify patients who are more likely to benefit from chemotherapy, potentially improving treatment outcomes.
How similar studies have performed: While the approach is innovative, the success of similar studies using miRNA tools for cancer prognosis is still being explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The informed consent has been obtained from the patient. * With confirmed diagnosis of stage II colon cancer. * With moderate/good ECOG health rating (PS): 0-1 score. * The patient receive no anti-cancer treatment before primary surgery. * The patient receive radical operation for colon cancer with negative margin. Exclusion Criteria: * With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. * With bad compliance or contraindication to enrollment. * Pregnant woman or lactating woman. * With contraindication to receive adjuvant chemotherapy.
Where this trial is running
Guangzhou, Guangdong
- FisrtSunYetsen — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Zehong Chen, master
- Email: Stevenchen8@qq.com
- Phone: +8613751773229
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.